Summary
Amgen Inc. reported solid financial results for the second quarter and first half of 2013, demonstrating continued revenue growth driven by key products like Neulasta®, Enbrel®, XGEVA®, and Prolia®. While overall revenues saw a modest increase, net income experienced a slight decrease in the quarter but a significant increase year-to-date, largely due to favorable tax benefits and a lower effective tax rate resulting from the reinstatement of the R&D tax credit and settlement of IRS examinations. The company's financial position remains strong, with substantial cash, cash equivalents, and marketable securities, though long-term debt is also significant. Amgen continued to return capital to shareholders through dividends and share repurchases, with a substantial amount remaining under its stock repurchase program. Key operational developments included the positive Phase 3 trial results for trebananib in ovarian cancer and FDA approval for XGEVA® in giant cell tumor of bone. The company also provided updates on its pipeline, including AMG 145 and talimogene laherparepvec, and noted a temporary suspension in enrollment for a biosimilar Herceptin® study. The company remains focused on advancing its therapeutic pipeline while managing operational expenses and regulatory complexities.
Financial Highlights
54 data points| Revenue | $4.68B |
| Cost of Revenue | $785.00M |
| Gross Profit | $3.81B |
| SG&A Expenses | $1.26B |
| Operating Expenses | $3.13B |
| Operating Income | $1.55B |
| Interest Expense | $241.00M |
| Net Income | $1.26B |
| EPS (Basic) | $1.67 |
| EPS (Diluted) | $1.65 |
| Shares Outstanding (Basic) | 752.00M |
| Shares Outstanding (Diluted) | 764.00M |
Key Highlights
- 1Total revenues increased by 5% year-over-year for both the three and six months ended June 30, 2013, reaching $4.7 billion and $8.9 billion, respectively.
- 2Product sales grew by 9% in the quarter and 8% year-to-date, driven by strong performance in Neulasta®, Enbrel®, XGEVA®, and Prolia®.
- 3Net income for the six months ended June 30, 2013, increased by 10% to $2.7 billion, primarily due to favorable tax impacts.
- 4Diluted Earnings Per Share (EPS) rose by 14% for the six months ended June 30, 2013, to $3.52, aided by increased net income and a reduced share count from repurchases.
- 5The company reported $22.0 billion in cash, cash equivalents, and marketable securities as of June 30, 2013, alongside $23.9 billion in total debt.
- 6Significant pipeline progress included positive Phase 3 results for trebananib and FDA approval for XGEVA® in a new indication.
- 7Amgen continued its commitment to capital return to shareholders, repurchasing $771 million in stock during the first quarter and paying dividends, with $1.6 billion remaining under its stock repurchase program.